Why Brazil should not be a site for AIDS vaccine trials

ARTHUR, L.O.; BESS, J.W.Jr. & SOWDER II, R.C. ET AL. Cellular proteins bound to immunodeficiency virus: implications for pathogenesis and vaccines. Science 1992; 258:1935.

BENSON, E.M. - Immune modulation in HIV infection: fact or fantasy? J. Acquir. Immune Defic. Syndr, 6(Suppl.l):S61-S67, 1993.

BLACKBURN, R.; CLERICI, M. & MANN, D. ET AL. Common sequence in HIV 1 GP41 and HLA class II beta chains can generate crossreactive autoantibodies with immunosupressive potential earlyin the course of HIV 1 infection. Ad Exp Med Biol, 303:63-69, 1991.

COHEN, J. Jitters jeopardize AIDS vaccine trials. Science, 262:980-981, 1993.

COHEN, J. How can viral variation be overcome? Science, 260:1260, 1993.

COHEN, J. What are the correlates of protection? Science, 260:1259, 1993.

COHEN, J. What HIV parts should be the basis of a vaccine? How should they be presented to the immune system? Science, 260:261, 1993.

COMITE BRASILEIRO SOBRE VACINAS DE HIV/AIDS. Plano Nacional Para Vacinas de HIV/AIDS: Pesquisa, Desenvolvimento e Avaliação no Brasil. Brasilia, Outubro 1992.

DOWDLE, W. Future vaccine policy and implications for efficacy trials. AIDS Nachrichten, 3193:IX Intl Conf Aids, Berlin, 1993.

GOGEON, M.L. & MONTAIGNER, L. Apoptosis in AIDS. Science, 260:1269, 1993.

HAN. J.; THOMPSON, P. & BEUTLER, B. Dexamethanose and pentoxifylline inhibit endotoxin - induced cachectin/tumour necrosis factor synthesis at separate pont in the signalling pathway. J Exp Med, 172:391-394, 1990.

JACOBSON, S.K.; CALNE, R.Y. & WREGHITT, T.G. Outcome of HIV infection in transplant patients on cyclosporin. Lancet, 337:794, 1991.

LEVY, J.A. HIV pathogenesis and long-term survival. AIDS, 7;1401-1410,1993.

McKENNA, N. A fair trial? Testing AIDS vaccines in the developing world. Panos AIDS Briefing nº2, November 1993.

WEISS, R.A. How does HIV cause AIDS? Science, 260:1273, 1993.